Drug Trial Radar · NCT07143448
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adults
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Aug 19, 2026
Primary completion
Mar 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- 35Pharma Inc., a GSK companyIndustry
- Sponsor type
- Industry
- First posted
- Aug 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1b/2 Study of HS235 Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of the Activin Signaling Inhibitor HS235 Added to Background Treatment in Adults with Pulmonary Arterial Hypertension (PAH)
Conditions
- Pulmonary Arterial Hypertension
Interventions
HS235Biological
Subcutaneous Injection
PlaceboOther
Subcutaneous Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Number of Adverse Events (AEs)Time frame: up to 29 weeks
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Investigational Site-102
Tampa, Florida · Recruiting
Investigational Site-101
Boston, Massachusetts · Recruiting
Investigational Site-104
Providence, Rhode Island · Recruiting
Investigational Site-305
Barcelona, Spain · Recruiting
Investigational Site- 301
Barcelona, Spain · Recruiting
Investigational Site-308
Madrid, Spain · Recruiting
Investigational Site-903
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.